Stay Informed on Corporate Sustainability

Explore industry news, insights, and updates from the Pharma Industry Awards.

Sort by

Genentech bets big on US soil amid policy storm

Author: Pharmaceutical Technology

As pricing pressures and political headwinds reshape the pharma landscape, Genentech is doubling down on American manufacturing.

VC interest remains strong in European life sciences

Author: Pharmaphorum

Despite market volatility, regulatory unknowns, and geopolitical headwinds, Europe’s life sciences sector is seeing sustained VC confidence.

Sanofi bets big on Alzheimer’s drug with bold biotech buyout 

Author: Biopharma Diver

Sanofi is doubling down on neuroscience with a $470 million acquisition of Vigil Neuroscience, securing full rights to an early-stage Alzheimer’s drug targeting the immune-linked protein TREM2.

Merck eyes global filing as TGCT drug shows strong QoL impact

Author: Pharmaceutical Technology

Merck KGaA is advancing its CSF-1R inhibitor pimicotinib toward global approval after a Phase III trial in TGCT patients delivered promising efficacy and functional outcomes.

BioNTech deepens UK ties with £1bn R&D expansion

Author: PMLive

BioNTech is betting big on British science, committing up to £1bn over the next decade to expand its regional R&D footprint.

Automation unlocks agility in microbiome and biotech R&D

Author: News-Medical

For pharma leaders chasing faster discovery and scale, manual colony picking has long been a bottleneck, slow, error-prone, and resource-intensive.

Regeneron’s $256m genetics play signals a deeper bet on precision health

Author: PMLive

Regeneron is set to acquire the core assets of 23andMe for $256 million, absorbing its genome services, biobank, and research operations following the latter’s bankruptcy proceedings.